J1458 Galsulfase injection
Also known as: galsulfase, Naglazyme
Galsulfase injection. A lysosomal sulfatase enzyme for mucopolysaccharidosis VI treatment.
In Plain Language
enzyme replacement therapy; genetic metabolic disease treatment
Clinical Context
Used for mucopolysaccharidosis VI (Maroteaux-Lamy syndrome), a lysosomal storage disease. Enzyme replacement therapy administered intravenously weekly.
RVU Information
CPT J1458 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.
Specialties
Frequently Asked Questions
What is CPT code J1458?
CPT J1458 (Galsulfase injection) is a J Codes (Drugs) code. Galsulfase injection. A lysosomal sulfatase enzyme for mucopolysaccharidosis VI treatment.
How is J1458 administered?
CPT J1458 is administered by a healthcare provider, typically via injection or infusion. Used for mucopolysaccharidosis VI (Maroteaux-Lamy syndrome), a lysosomal storage disease. Enzyme replacement therapy administered intravenously weekly. It is used by Genetics, Pediatrics, Internal Medicine.
When is CPT J1458 used?
Used for mucopolysaccharidosis VI (Maroteaux-Lamy syndrome), a lysosomal storage disease. Enzyme replacement therapy administered intravenously weekly.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.